ArticleJournal of racial and ethnic health disparities2025
Racial Disparities in Kidney Transplant Outcomes Among Black and White Recipients Treated with Cyclosporine and mTOR Inhibitors.
Article in Journal of racial and ethnic health disparities, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances.Annals of hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRacial disparities in kidney transplant outcomes remain a persistent challenge despite advances in immunosuppression. This study examined short- and intermediate-term graft outcomes among Black and White recipients receiving cyclosporine plus mTOR inhibitor based regimens.
methodsUsing the TriNetX Global Collaborative Network, we identified adult kidney transplant recipients, stratified cohorts by race (Black vs. White), matched 1:1 on demographics, comorbidities, and concomitant medications. Outcomes included transplant rejection, graft failure, and all-cause mortality at one year and between one to three years post-transplant. Analyses included risk differences, hazard ratios (HR), and Kaplan-Meier survival estimates.
resultsMatched cohorts included 305 Black and 305 White recipients. At one year, Black patients experienced significantly higher rejection (23.6% vs. 16.1%; HR 1.50, 95% CI 1.04-2.16) and graft failure (22.6% vs. 15.1%; HR 1.54, 95% CI 1.06-2.24), mortality was similar (6.9% vs. 8.9%, p = 0.367). Between one and three years, disparities persisted: rejection occurred in 21.3% of Black vs. 13.8% of White recipients (HR 1.69, 95% CI 1.15-2.49), and failure in 20.7% vs. 12.5% (HR 1.79, 95% CI 1.20-2.68). Mortality remained nonsignificant (10.2% vs. 8.2%, p = 0.400).
conclusionDespite matched clinical profiles and immunosuppressive regimens, Black kidney transplant recipients experienced persistently higher rates of rejection and graft failure. These findings highlight persistent disparities in transplant outcomes and the need for equity-driven interventions to improve equity in graft survival.
Indexed as
Identifiers
41296288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.